Host |
Mouse |
Klon |
JC159 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cell Membrane |
Glycophorin A (CD235a)
|
Diagnostic Biosystems |
JC159 |
0.1 ml |
Concentrate |
CE/IVD |
MOB066-01 |
-
|
Host |
Mouse |
Klon |
JC159 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cell Membrane |
Glycophorin A (CD235a)
|
Diagnostic Biosystems |
JC159 |
0.5 ml |
Concentrate |
CE/IVD |
MOB066-05 |
-
|
Host |
Mouse |
Klon |
JC159 |
Format |
Ready-to-use |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cell Membrane |
Glycophorin A (CD235a)
|
Diagnostic Biosystems |
JC159 |
6 ml |
Ready-to-use |
CE/IVD |
PDM124 |
-
|
Host |
Mouse |
Klon |
BRIC10 |
Format |
Purified |
Methode |
WB, FL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human erythrocytes |
Glycophorin C (CD236R)
|
Zytomed Systems GmbH |
BRIC10 |
200 µg |
Purified |
RUO |
607-0164 |
-
|
Host |
Mouse |
Klon |
Ret40f |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:15 - 1:30 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
Glycophorin C (CD236R)
|
Diagnostic Biosystems |
Ret40f |
1 ml |
Concentrate |
CE/IVD |
MOB067 |
-
|
Host |
Mouse |
Klon |
Ret40f |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:15 - 1:30 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
Glycophorin C (CD236R)
|
Diagnostic Biosystems |
Ret40f |
0.1 ml |
Concentrate |
CE/IVD |
MOB067-01 |
-
|
Host |
Mouse |
Klon |
Ret40f |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:15 - 1:30 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
Glycophorin C (CD236R)
|
Diagnostic Biosystems |
Ret40f |
0.5 ml |
Concentrate |
CE/IVD |
MOB067-05 |
-
|
Host |
Mouse |
Klon |
Ret40f |
Format |
Ready-to-use |
Methode |
P |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
Glycophorin C (CD236R)
|
Diagnostic Biosystems |
Ret40f |
6 ml |
Ready-to-use |
CE/IVD |
PDM578 |
-
|
Host |
Mouse |
Klon |
Ret40f |
Format |
Ready-to-use |
Methode |
P |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
Glycophorin C (CD236R)
|
Diagnostic Biosystems |
Ret40f |
25 ml |
Ready-to-use |
CE/IVD |
PDM578-25 |
-
|
Host |
Mouse |
Klon |
YP7 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Thyroid carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
IgG1 kappa |
Lokalisation |
Cytoplasm |
Glypican-3
|
Diagnostic Biosystems |
YP7 |
1 ml |
Concentrate |
CE/IVD |
MOB561 |
-
|
Host |
Mouse |
Klon |
YP7 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Thyroid carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
IgG1 kappa |
Lokalisation |
Cytoplasm |
Glypican-3
|
Diagnostic Biosystems |
YP7 |
0.1 ml |
Concentrate |
CE/IVD |
MOB561-01 |
-
|
Host |
Mouse |
Klon |
YP7 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Thyroid carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
IgG1 kappa |
Lokalisation |
Cytoplasm |
Glypican-3
|
Diagnostic Biosystems |
YP7 |
0.5 ml |
Concentrate |
CE/IVD |
MOB561-05 |
-
|
Host |
Mouse |
Klon |
YP7 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Thyroid carcinoma |
Verdünnung |
- |
Isotyp |
IgG1 kappa |
Lokalisation |
Cytoplasm |
Glypican-3
|
Diagnostic Biosystems |
YP7 |
6 ml |
Ready-to-use |
CE/IVD |
PDM561 |
-
|
Host |
Mouse |
Klon |
YP7 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Thyroid carcinoma |
Verdünnung |
- |
Isotyp |
IgG1 kappa |
Lokalisation |
Cytoplasm |
Glypican-3
|
Diagnostic Biosystems |
YP7 |
25 ml |
Ready-to-use |
CE/IVD |
PDM561-25 |
-
|
Host |
Mouse |
Klon |
1G12 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Hepatocellular carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
A fragment containing the last 70 amino acids of the core glypican-3 protein |
Lokalisation |
Cytoplasm and Cell membrane |
Glypican 3
|
Zeta Corporation |
1G12 |
1ml |
Concentrate |
CE/IVD |
Z2103ML |
-
|
Host |
Mouse |
Klon |
1G12 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Hepatocellular carcinoma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
A fragment containing the last 70 amino acids of the core glypican-3 protein |
Lokalisation |
Cytoplasm and Cell membrane |
Glypican 3
|
Zeta Corporation |
1G12 |
7 ml |
Ready-to-use |
CE/IVD |
Z2103MP |
-
|
Host |
Mouse |
Klon |
1G12 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Hepatocellular carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
A fragment containing the last 70 amino acids of the core glypican-3 protein |
Lokalisation |
Cytoplasm and Cell membrane |
Glypican 3
|
Zeta Corporation |
1G12 |
0.5 ml |
Concentrate |
CE/IVD |
Z2103MS |
-
|
Host |
Mouse |
Klon |
1G12 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Hepatocellular carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
A fragment containing the last 70 amino acids of the core glypican-3 protein |
Lokalisation |
Cytoplasm and Cell membrane |
Glypican 3
|
Zeta Corporation |
1G12 |
0.1 ml |
Concentrate |
CE/IVD |
Z2103MT |
-
|
Host |
Mouse |
Klon |
ZM138 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Hepatocellular carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human GPC3 protein fragment |
Lokalisation |
Cytoplasm and Cell membrane |
Glypican 3
|
Zeta Corporation |
ZM138 |
1.0 ml |
Concentrate |
CE/IVD |
Z2449ML |
-
|
Host |
Mouse |
Klon |
ZM138 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Hepatocellular carcinoma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human GPC3 protein fragment |
Lokalisation |
Cytoplasm and Cell membrane |
Glypican 3
|
Zeta Corporation |
ZM138 |
7 ml |
Ready-to-use |
CE/IVD |
Z2449MP |
-
|
Host |
Mouse |
Klon |
ZM138 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Hepatocellular carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human GPC3 protein fragment |
Lokalisation |
Cytoplasm and Cell membrane |
Glypican 3
|
Zeta Corporation |
ZM138 |
0.5 ml |
Concentrate |
CE/IVD |
Z2449MS |
-
|
Host |
Mouse |
Klon |
ZM138 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Hepatocellular carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human GPC3 protein fragment |
Lokalisation |
Cytoplasm and Cell membrane |
Glypican 3
|
Zeta Corporation |
ZM138 |
0.1 ml |
Concentrate |
CE/IVD |
Z2449MT |
-
|
Host |
Goat |
Klon |
polyclonal |
Format |
Purified |
Methode |
F, EL, WB |
Isotyp |
Goat IgG |
Verdünnung |
Purified canine IgA |
Goat anti-Dog IgA
|
Zytomed Systems GmbH |
polyclonal |
1 mg |
Purified |
RUO |
609-0032 |
-
|
Host |
Rat |
Klon |
RB6-8C5 |
Format |
Purified |
Methode |
F, WB, IP, FL |
Isotyp |
Rat IgG2b |
Verdünnung |
Normal murine bone marrow cells |
Gr-1
|
Zytomed Systems GmbH |
RB6-8C5 |
250 µg |
Purified |
RUO |
607-0168 |
-
|
Host |
Mouse |
Klon |
HIS48 |
Format |
TCS |
Methode |
F, FL |
Isotyp |
Mouse IgM |
Verdünnung |
PVG rat spleen cell suspension |
Granulocytes & Erythroid Cells
|
Zytomed Systems GmbH |
HIS48 |
2 ml |
TCS |
RUO |
607-0199 |
-
|
Host |
Mouse |
Klon |
GB7 |
Format |
Purified |
Methode |
WB, P |
Vorbehandlung |
Citrate |
Verdünnung |
1:50 - 1:200 (P) |
Isotyp |
Mouse IgG2a |
Verdünnung |
Recombinant Granzyme B |
Granzyme B
|
Zytomed Systems GmbH |
GB7 |
100 µg |
Purified |
RUO |
607-0205 |
-
|
Host |
Mouse |
Klon |
11F1 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Spleen or tonsil |
Verdünnung |
1:50 |
Isotyp |
IgG2a |
Verdünnung |
Recombinant protein corresponding to the Nterminus of granzyme B |
Lokalisation |
Cytoplasmic lytic granules |
Granzyme B
|
Biocare Medical |
11F1 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3202A |
-
|
Host |
Mouse |
Klon |
11F1 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Spleen or tonsil |
Verdünnung |
1:50 |
Isotyp |
IgG2a |
Verdünnung |
Recombinant protein corresponding to the Nterminus of granzyme B |
Lokalisation |
Cytoplasmic lytic granules |
Granzyme B
|
Biocare Medical |
11F1 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3202B |
-
|
Host |
Mouse |
Klon |
11F1 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Spleen or tonsil |
Verdünnung |
- |
Isotyp |
IgG2a |
Verdünnung |
Recombinant protein corresponding to the Nterminus of granzyme B |
Lokalisation |
Cytoplasmic lytic granules |
Granzyme B
|
Biocare Medical |
11F1 |
6 ml |
Ready-to-use |
CE/IVD |
API3202AA |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hodgkin´s Lymphoma |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Granular Cytoplasmic |
Granzyme B
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR050 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hodgkin´s Lymphoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Granular Cytoplasmic |
Granzyme B
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP105 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hodgkin´s Lymphoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Granular Cytoplasmic |
Granzyme B
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP105-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hodgkin´s Lymphoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Granular Cytoplasmic |
Granzyme B
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP105-05 |
-
|
Host |
Mouse |
Klon |
ZM66 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human GZMB protein fragment (around aa 73-187) |
Lokalisation |
Granular Cytoplasm |
Granzyme B
|
Zeta Corporation |
ZM66 |
1.0 ml |
Concentrate |
CE/IVD |
Z2376ML |
-
|
Host |
Mouse |
Klon |
ZM66 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil. |
Verdünnung |
- |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human GZMB protein fragment (around aa 73-187) |
Lokalisation |
Granular Cytoplasm |
Granzyme B
|
Zeta Corporation |
ZM66 |
7 ml |
Ready-to-use |
CE/IVD |
Z2376MP |
-
|
Host |
Mouse |
Klon |
ZM66 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human GZMB protein fragment (around aa 73-187) |
Lokalisation |
Granular Cytoplasm |
Granzyme B
|
Zeta Corporation |
ZM66 |
0.5 ml |
Concentrate |
CE/IVD |
Z2376MS |
-
|
Host |
Mouse |
Klon |
ZM66 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human GZMB protein fragment (around aa 73-187) |
Lokalisation |
Granular Cytoplasm |
Granzyme B
|
Zeta Corporation |
ZM66 |
0.1 ml |
Concentrate |
CE/IVD |
Z2376MT |
-
|
Host |
Mouse |
Klon |
ZM140 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Pituitary. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
A recombinant human Growth Hormone (GH) fragment (aa58-187) |
Lokalisation |
Cytoplasm |
Growth Hormone
|
Zeta Corporation |
ZM140 |
1 ml |
Concentrate |
CE/IVD |
Z2451ML |
-
|
Host |
Mouse |
Klon |
ZM140 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Pituitary. |
Verdünnung |
- |
Isotyp |
IgG2b /κ |
Verdünnung |
A recombinant human Growth Hormone (GH) fragment (aa58-187) |
Lokalisation |
Cytoplasm |
Growth Hormone
|
Zeta Corporation |
ZM140 |
7 ml |
Ready-to-use |
CE/IVD |
Z2451MP |
-
|
Host |
Mouse |
Klon |
ZM140 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Pituitary. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
A recombinant human Growth Hormone (GH) fragment (aa58-187) |
Lokalisation |
Cytoplasm |
Growth Hormone
|
Zeta Corporation |
ZM140 |
0.5 ml |
Concentrate |
CE/IVD |
Z2451MS |
-
|
Host |
Mouse |
Klon |
ZM140 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Pituitary. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
A recombinant human Growth Hormone (GH) fragment (aa58-187) |
Lokalisation |
Cytoplasm |
Growth Hormone
|
Zeta Corporation |
ZM140 |
0.1 ml |
Concentrate |
CE/IVD |
Z2451MT |
-
|
Host |
Rabbit |
Klon |
C36B11 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Diva modified Citrate |
Positivkontrolle |
Ovarian cancer |
Verdünnung |
1:100 |
Isotyp |
IgG |
Lokalisation |
Nucleus |
H3K27me3 [C36B11]
|
Biocare Medical |
C36B11 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3249A |
-
|
Host |
Rabbit |
Klon |
C36B11 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Diva modified Citrate |
Positivkontrolle |
Ovarian cancer |
Verdünnung |
1:100 |
Isotyp |
IgG |
Lokalisation |
Nucleus |
H3K27me3 [C36B11]
|
Biocare Medical |
C36B11 |
1 ml |
Concentrate |
CE/IVD |
ACI3249C |
-
|
Host |
Rabbit |
Klon |
C36B11 |
Format |
Ready-to-use |
Methode |
P |
Positivkontrolle |
Ovarian cancer |
Verdünnung |
- |
Isotyp |
IgG |
Lokalisation |
Nucleus |
H3K27me3 [C36B11]
|
Biocare Medical |
C36B11 |
7 ml |
Ready-to-use |
CE/IVD |
ALI3249G7 |
-
|
Host |
Rabbit |
Klon |
C36B11 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Diva modified Citrate |
Positivkontrolle |
Ovarian cancer |
Verdünnung |
- |
Isotyp |
IgG |
Lokalisation |
Nucleus |
H3K27me3 [C36B11]
|
Biocare Medical |
C36B11 |
6 ml |
Ready-to-use |
CE/IVD |
API3249AA |
-
|
Host |
Rabbit |
Klon |
C36B11 |
Format |
Ready-to-use |
Methode |
P |
Positivkontrolle |
Ovarian cancer |
Verdünnung |
- |
Isotyp |
IgG |
Lokalisation |
Nucleus |
H3K27me3 [C36B11]
|
Biocare Medical |
C36B11 |
6 ml |
Ready-to-use |
CE/IVD |
AVI3249G |
-
|
Host |
Mouse |
Klon |
DBA.44 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:15 - 1:30 |
Isotyp |
Mouse IgM |
Lokalisation |
Cytoplasm, Cell Membrane |
Hairy Cell Leukemia
|
Diagnostic Biosystems |
DBA.44 |
1 ml |
Concentrate |
CE/IVD |
MOB200 |
-
|
Host |
Mouse |
Klon |
DBA.44 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:15 - 1:30 |
Isotyp |
Mouse IgM |
Lokalisation |
Cytoplasm, Cell Membrane |
Hairy Cell Leukemia
|
Diagnostic Biosystems |
DBA.44 |
0.1 ml |
Concentrate |
CE/IVD |
MOB200-01 |
-
|
Host |
Mouse |
Klon |
DBA.44 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:15 - 1:30 |
Isotyp |
Mouse IgM |
Lokalisation |
Cytoplasm, Cell Membrane |
Hairy Cell Leukemia
|
Diagnostic Biosystems |
DBA.44 |
0.5 ml |
Concentrate |
CE/IVD |
MOB200-05 |
-
|
Host |
Mouse |
Klon |
DBA.44 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgM |
Lokalisation |
Cytoplasm, Cell Membrane |
Hairy Cell Leukemia
|
Diagnostic Biosystems |
DBA.44 |
6 ml |
Ready-to-use |
CE/IVD |
PDM024 |
-
|